Medicenna Therapeutics Corp.
MDNAF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807983
No open-market purchases or sales by Medicenna Therapeutics Corp. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Medicenna Therapeutics Corp. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 28 | 26 | −2 |
| Shares | 10.9M | 9.61M | −1.34M (−12.2%) |
| Value | $4.75M | $2.45M | −$2.30M (−48.4%) |
New holders (2)
Institutions that held Medicenna Therapeutics Corp. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 27,626 | $7.90K | 0.00% |
| Millennium Management LLC | 24,988 | $7.14K | 0.00% |
Sold out (4)
Institutions that held Medicenna Therapeutics Corp. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| DAFNA Capital Management LLC | 660,000 | $317.9K |
| Annandale Capital, LLC | 40,000 | $19.0K |
| Newman Dignan & Sheerar, Inc. | 12,915 | $6.22K |
| National Bank of Canada | 600 | $272 |